Palvella Therapeutics, Inc. Common Stock (PVLA)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 29
- Market Cap
- $2.2B
About Palvella Therapeutics, Inc. Common Stock
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
SentiSense also tracks daily options readings for Palvella Therapeutics, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Palvella Therapeutics, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.